Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS).

IF 3.9 2区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Marcin Ziółkowski, Jakub Ratajczak, Karolina Obońska, Piotr Adamski, Maciej Banach, Krzysztof Chlebus, Maciej Grymuza, Klaudyna Grzelakowska, Piotr Jankowski, Jacek Konarski, Ewa Laskowska, Piotr Niezgoda, Małgorzata Ostrowska, Elżbieta Ozorowska, Przemysław Podhajski, Jacek Przybylski, Grzegorz Skonieczny, Bożena Sosnowska, Łukasz Szarpak, Małgorzata Topolska, Julia Umińska, Magdalena Krintus, Jacek Kryś, Jacek Kubica
{"title":"Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS).","authors":"Marcin Ziółkowski, Jakub Ratajczak, Karolina Obońska, Piotr Adamski, Maciej Banach, Krzysztof Chlebus, Maciej Grymuza, Klaudyna Grzelakowska, Piotr Jankowski, Jacek Konarski, Ewa Laskowska, Piotr Niezgoda, Małgorzata Ostrowska, Elżbieta Ozorowska, Przemysław Podhajski, Jacek Przybylski, Grzegorz Skonieczny, Bożena Sosnowska, Łukasz Szarpak, Małgorzata Topolska, Julia Umińska, Magdalena Krintus, Jacek Kryś, Jacek Kubica","doi":"10.1186/s12944-025-02712-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperlipidemia is the most prevalent cardiovascular (CV) risk factors. We aimed to analyze the distribution of lipid parameters and clinical variables associated with elevated and non-elevated selected lipid factors in a cohort of all consecutive patients whose lipid profile was assessed at a multi-specialist clinical center.</p><p><strong>Materials and methods: </strong>This cross-sectional study analyzed electronic medical records of consecutive patients treated between March and November 2024. Lipid parameters measured included: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (apoB), and lipoprotein (a) [Lp(a)]. Non-high-density lipoprotein cholesterol (non-HDL-C) was calculated as TC-HDL-C. We used multivariate analysis to identify factors associated with LDL-C, TG, and Lp(a) concentrations.</p><p><strong>Results: </strong>A total of 10,597 patients were included in the analysis. The median lipid concentrations (mg/dL) were: TC 162 (IQR 132-198), LDL-C 94 (IQR 69-129), non-HDL-C 112 (IQR 88-146), apoB 78 (IQR 63-99), and Lp(a) 11 (IQR 5-29). Elevated LDL-C > 100 mg/dL was observed in 45.7% of patients, non-HDL-C > 130 mg/dL in 35.1%, and apoB > 100 mg/dL in 23.2%. A discordance between LDL-C and apoB concentrations was present in 23.7% of patients (p < 0.001), while LDL-C/non-HDL-C and apoB/non-HDL-C discordance rates were 13% and 12.6%, respectively (p < 0.001). Patients at very high CV risk had lower TC, LDL-C, non-HDL-C, and apoB concentrations compared to those with low-to-moderate and high CV risk (p < 0.001) and showed the highest median Lp(a) concentration of 13 mg/dL (IQR 5-31; p = 0.01). Goal achievements of LDL-C < 100 mg/dL, TG < 150 mg/dL, and Lp(a) < 30 mg/dL were associated with lipid-lowering treatment [OR 1.32 (95% CI 1.12-1.52)], atrial fibrillation [OR 1.31 (95% CI 1.11-1.54)], chronic coronary syndromes [OR 1.27 (95% CI 1.05-1.52)], smoking [OR 0.78 (95% CI 0.65-0.95)], BMI [OR 0.98 (95% CI 0.96-0.99)], and age [OR 1.006 (95% CI 1.002-1.009)].</p><p><strong>Conclusion: </strong>The highest proportion of patients with results within the normal range was observed for apoB and the lowest for LDL-C. The highest discordance was observed between apoB/LDL-C, with similar discordance rates between LDL-C/non-HDL-C and apoB/non-HDL-C. Lipid profile control was associated with BMI, atrial fibrillation, age, chronic coronary syndrome, aortic stenosis, diabetes, male gender, lipid-lowering therapy, and smoking. These findings highlight the complexity of lipid management.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"300"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482036/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lipids in Health and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12944-025-02712-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hyperlipidemia is the most prevalent cardiovascular (CV) risk factors. We aimed to analyze the distribution of lipid parameters and clinical variables associated with elevated and non-elevated selected lipid factors in a cohort of all consecutive patients whose lipid profile was assessed at a multi-specialist clinical center.

Materials and methods: This cross-sectional study analyzed electronic medical records of consecutive patients treated between March and November 2024. Lipid parameters measured included: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (apoB), and lipoprotein (a) [Lp(a)]. Non-high-density lipoprotein cholesterol (non-HDL-C) was calculated as TC-HDL-C. We used multivariate analysis to identify factors associated with LDL-C, TG, and Lp(a) concentrations.

Results: A total of 10,597 patients were included in the analysis. The median lipid concentrations (mg/dL) were: TC 162 (IQR 132-198), LDL-C 94 (IQR 69-129), non-HDL-C 112 (IQR 88-146), apoB 78 (IQR 63-99), and Lp(a) 11 (IQR 5-29). Elevated LDL-C > 100 mg/dL was observed in 45.7% of patients, non-HDL-C > 130 mg/dL in 35.1%, and apoB > 100 mg/dL in 23.2%. A discordance between LDL-C and apoB concentrations was present in 23.7% of patients (p < 0.001), while LDL-C/non-HDL-C and apoB/non-HDL-C discordance rates were 13% and 12.6%, respectively (p < 0.001). Patients at very high CV risk had lower TC, LDL-C, non-HDL-C, and apoB concentrations compared to those with low-to-moderate and high CV risk (p < 0.001) and showed the highest median Lp(a) concentration of 13 mg/dL (IQR 5-31; p = 0.01). Goal achievements of LDL-C < 100 mg/dL, TG < 150 mg/dL, and Lp(a) < 30 mg/dL were associated with lipid-lowering treatment [OR 1.32 (95% CI 1.12-1.52)], atrial fibrillation [OR 1.31 (95% CI 1.11-1.54)], chronic coronary syndromes [OR 1.27 (95% CI 1.05-1.52)], smoking [OR 0.78 (95% CI 0.65-0.95)], BMI [OR 0.98 (95% CI 0.96-0.99)], and age [OR 1.006 (95% CI 1.002-1.009)].

Conclusion: The highest proportion of patients with results within the normal range was observed for apoB and the lowest for LDL-C. The highest discordance was observed between apoB/LDL-C, with similar discordance rates between LDL-C/non-HDL-C and apoB/non-HDL-C. Lipid profile control was associated with BMI, atrial fibrillation, age, chronic coronary syndrome, aortic stenosis, diabetes, male gender, lipid-lowering therapy, and smoking. These findings highlight the complexity of lipid management.

Abstract Image

Abstract Image

Abstract Image

波兰一家大型多专科医院患者的脂质概况和与选定脂质参数控制相关的变量- Jurasz脂质研究(JLS)。
背景:高脂血症是最常见的心血管(CV)危险因素。我们的目的是分析血脂参数的分布和与选定的血脂因子升高和非升高相关的临床变量,这些患者在一个多专科临床中心进行了血脂评估。材料和方法:本横断面研究分析了2024年3月至11月期间连续治疗的患者的电子病历。脂质参数测量包括:总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、载脂蛋白B (apoB)和脂蛋白(a) [Lp(a)]。非高密度脂蛋白胆固醇(non-HDL-C)计算为TC-HDL-C。我们使用多变量分析来确定与LDL-C、TG和Lp(a)浓度相关的因素。结果:共纳入10597例患者。中位脂质浓度(mg/dL)为:TC 162 (IQR 132-198)、LDL-C 94 (IQR 69-129)、非hdl - c 112 (IQR 88-146)、apoB 78 (IQR 63-99)和Lp(a) 11 (IQR 5-29)。45.7%的患者LDL-C升高100mg /dL, 35.1%的患者非hdl - c升高130mg /dL, 23.2%的患者载脂蛋白升高>升高100mg /dL。23.7%的患者LDL-C和载脂蛋白ob浓度不一致(p结论:载脂蛋白ob在正常范围内的比例最高,LDL-C在正常范围内的比例最低。apoB/LDL-C之间的差异最大,LDL-C/非hdl - c和apoB/非hdl - c之间的差异率相似。脂质控制与BMI、房颤、年龄、慢性冠状动脉综合征、主动脉瓣狭窄、糖尿病、男性、降脂治疗和吸烟有关。这些发现突出了血脂管理的复杂性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lipids in Health and Disease
Lipids in Health and Disease 生物-生化与分子生物学
CiteScore
7.70
自引率
2.20%
发文量
122
审稿时长
3-8 weeks
期刊介绍: Lipids in Health and Disease is an open access, peer-reviewed, journal that publishes articles on all aspects of lipids: their biochemistry, pharmacology, toxicology, role in health and disease, and the synthesis of new lipid compounds. Lipids in Health and Disease is aimed at all scientists, health professionals and physicians interested in the area of lipids. Lipids are defined here in their broadest sense, to include: cholesterol, essential fatty acids, saturated fatty acids, phospholipids, inositol lipids, second messenger lipids, enzymes and synthetic machinery that is involved in the metabolism of various lipids in the cells and tissues, and also various aspects of lipid transport, etc. In addition, the journal also publishes research that investigates and defines the role of lipids in various physiological processes, pathology and disease. In particular, the journal aims to bridge the gap between the bench and the clinic by publishing articles that are particularly relevant to human diseases and the role of lipids in the management of various diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信